A study from Yale University today in JAMA Network Open reveals substantial protection by the preventive drug nirsevimab ...
Estimated effectiveness was 65% against hospitalization, 74% against pediatric intensive care unit admission, and 64% against ...
It teased the positive results in July. Along with Beyfortus (nirsevimab), it is also a potential rival to Pfizer's RSV vaccine Abrysvo, which can be given to women during pregnancy to protect ...
Sanofi’s plan to become a dominant player in the respiratory syncytial virus (RSV) market has moved a step closer, with FDA approval of Beyfortus for the prevention of RSV disease in infants.
Yun Ki-wook, a professor in SNUH's Department of Pediatric Infectious Diseases, discusses the domestic release of Beyfortus, an antibody treatment for respiratory syncytial virus, during a press ...
The beyfortus market size is expected to see XX (FCAGR) in the next few years. It will grow to $XX million in 2029 at a compound annual growth rate (CAGR) of XX ...
LONDON, GREATER LONDON, UNITED KINGDOM, March 4, 2025 /EINPresswire / -- How Has the Beyfortus Market Expanded in Recent Years? The Beyfortus market has experienced significant growth, driven by ...